Severe COVID-19 in an APS1 patient with interferon autoantibodies treated with plasmapheresis - 05/07/21
Doi : 10.1016/j.jaci.2021.03.034
Andri Lemarquis, MD, PhD a, b 
, Tessa Campbell, PhD c, d, Maribel Aranda-Guillén, MSc e, Viktoria Hennings, MSc a, b, Petter Brodin, MD, PhD f, Olle Kämpe, MD, PhD e, Kaj Blennow, MD, PhD g, h, Henrik Zetterberg, MD, PhD g, h, i, j, Christine Wennerås, MD, PhD k, l, Kristina Eriksson, PhD b, Nils Landegren, MD, PhD e, m, Yenan Bryceson, PhD c, d, n, Stefan Berg, MD, PhD a, o, Olov Ekwall, MD, PhD a, b
, Tessa Campbell, PhD c, d, Maribel Aranda-Guillén, MSc e, Viktoria Hennings, MSc a, b, Petter Brodin, MD, PhD f, Olle Kämpe, MD, PhD e, Kaj Blennow, MD, PhD g, h, Henrik Zetterberg, MD, PhD g, h, i, j, Christine Wennerås, MD, PhD k, l, Kristina Eriksson, PhD b, Nils Landegren, MD, PhD e, m, Yenan Bryceson, PhD c, d, n, Stefan Berg, MD, PhD a, o, Olov Ekwall, MD, PhD a, b a Department of Pediatrics, Institute of Clinical Sciences, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
b Department of Rheumatology and Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
c Centre for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institute, Stockholm, Sweden
d Division of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden
e Centre for Molecular Medicine, Department of Medicine (Solna), Karolinska Institute, Stockholm, Sweden
f Science for Life Laboratory, Department of Women’s and Children’s Health, Karolinska Institute, Solna, Sweden
g Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden
h Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
i Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, United Kingdom
j UK Dementia Research Institute at UCL, London, United Kingdom
k Department of Infectious Diseases, Institute of Biomedicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
l Department of Clinical Microbiology, Sahlgrenska University Hospital, Gothenburg, Sweden
m Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden
n Broegelmann Research Laboratory, Department of Clinical Sciences, University of Bergen, Bergen, Norway
o Department of Pediatrics, Queen Silvia Children’s Hospital, Sahlgrenska University Hospital, Gothenburg, Sweden
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Le texte complet de cet article est disponible en PDF.
| This study was supported by grants from the Swedish Research Council (grant no. 2018-02752) and from the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (grant nos. 76800 and 76210). |
|
| Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest. |
© 2021
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 148 - N° 1
P. 96-98 - juillet 2021 Retour au numéro
Article précédent
- Basophil reactivity to BNT162b2 is mediated by PEGylated lipid nanoparticles in patients with PEG allergy
- Alexander Troelnikov, Griffith Perkins, Chino Yuson, Aida Ahamdie, Summaya Balouch, Plinio R. Hurtado, Pravin Hissaria
- Deletion of IL-4R? signaling on B cells limits hyperresponsiveness depending on antigen load
- Sabelo Hadebe, Jermaine Khumalo, Sandisiwe Mangali, Nontobeko Mthembu, Hlumani Ndlovu, Martyna Scibiorek, Amkele Ngomti, Frank Kirstein, Frank Brombacher
Bienvenue sur EM-consulte, la référence des professionnels de santé.